CN115151258A - 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗 - Google Patents

使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗 Download PDF

Info

Publication number
CN115151258A
CN115151258A CN202080098004.1A CN202080098004A CN115151258A CN 115151258 A CN115151258 A CN 115151258A CN 202080098004 A CN202080098004 A CN 202080098004A CN 115151258 A CN115151258 A CN 115151258A
Authority
CN
China
Prior art keywords
human
ilt4
monoclonal antibody
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080098004.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·阿尔图拉
P·E·布兰迪什
R·F·佩里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Merck Sharp and Dohme BV
Original Assignee
Sanitary Material R&d Management Co ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd, Merck Sharp and Dohme BV filed Critical Sanitary Material R&d Management Co ltd
Publication of CN115151258A publication Critical patent/CN115151258A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080098004.1A 2020-01-02 2020-12-18 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗 Pending CN115151258A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956469P 2020-01-02 2020-01-02
US62/956469 2020-01-02
PCT/US2020/065799 WO2021138079A1 (en) 2020-01-02 2020-12-18 Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof.

Publications (1)

Publication Number Publication Date
CN115151258A true CN115151258A (zh) 2022-10-04

Family

ID=76687248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080098004.1A Pending CN115151258A (zh) 2020-01-02 2020-12-18 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗

Country Status (10)

Country Link
US (1) US20230058779A1 (https=)
EP (1) EP4084794A4 (https=)
JP (1) JP2023510199A (https=)
KR (1) KR20220137007A (https=)
CN (1) CN115151258A (https=)
AU (1) AU2020416715A1 (https=)
BR (1) BR112022013143A2 (https=)
CA (1) CA3166571A1 (https=)
MX (1) MX2022008216A (https=)
WO (1) WO2021138079A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US20250011453A1 (en) * 2021-07-20 2025-01-09 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN114191547A (zh) * 2021-12-23 2022-03-18 中山大学 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20180298096A1 (en) * 2017-04-07 2018-10-18 Merck Sharp & Dohme Corp. Anti-ILT4 Antibodies and Antigen-Binding Fragments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20180298096A1 (en) * 2017-04-07 2018-10-18 Merck Sharp & Dohme Corp. Anti-ILT4 Antibodies and Antigen-Binding Fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C-H. LEE等: "A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma", 《ANNALS OF ONCOLOGY》, pages 295 *

Also Published As

Publication number Publication date
US20230058779A1 (en) 2023-02-23
CA3166571A1 (en) 2021-07-08
BR112022013143A2 (pt) 2022-09-20
WO2021138079A1 (en) 2021-07-08
MX2022008216A (es) 2022-08-04
JP2023510199A (ja) 2023-03-13
EP4084794A1 (en) 2022-11-09
EP4084794A4 (en) 2023-10-25
KR20220137007A (ko) 2022-10-11
AU2020416715A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
CN115151258A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
JP2023515675A (ja) Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
JP2025156341A (ja) ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
CN116406288A (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
CN113244388A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
US20250011453A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US20200255506A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
RU2844463C1 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации антагониста pd-1, ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
US20230062308A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
WO2024177899A1 (en) Methods for treating non-small cell lung cancer with anti-pd-1 antibodies
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
TW202535406A (zh) 用於治療肺癌之a2a受體拮抗劑
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
CN121443321A (zh) 治疗组合及其用途和治疗方法
IL322944A (en) Methods for treating melanoma using anti-CTLA4 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221004

WD01 Invention patent application deemed withdrawn after publication